tetano
Editor, Senior Moderator
Semin Oncol
. 2021 Jan 2;S0093-7754(20)30124-X.
doi: 10.1053/j.seminoncol.2020.12.003. Online ahead of print.
Rare SARS-CoV-2 antibody development in cancer patients
Louisa Hempel[SUP] 1 [/SUP], Jakob Molnar[SUP] 2 [/SUP], Sebastian Robert[SUP] 3 [/SUP], Julia Veloso[SUP] 3 [/SUP], Zeljka Trepotec[SUP] 4 [/SUP], Sofie Englisch[SUP] 4 [/SUP], Philip Weinzierl[SUP] 4 [/SUP], Cordula Schick[SUP] 4 [/SUP], Valeria Milani[SUP] 5 [/SUP], Katrin Schweneker[SUP] 6 [/SUP], Bastian Fleischmann[SUP] 7 [/SUP], Josef Scheiber[SUP] 8 [/SUP], Beate Gandorfer[SUP] 4 [/SUP], Axel Kleespies[SUP] 2 [/SUP], Dirk Hempel[SUP] 9 [/SUP], Kristina Riedmann[SUP] 10 [/SUP], Armin Piehler[SUP] 4 [/SUP]
Affiliations
Abstract
SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers' specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.
Keywords: COVID-19; Cancer; Immunity; SARS-CoV2 antibody development.
. 2021 Jan 2;S0093-7754(20)30124-X.
doi: 10.1053/j.seminoncol.2020.12.003. Online ahead of print.
Rare SARS-CoV-2 antibody development in cancer patients
Louisa Hempel[SUP] 1 [/SUP], Jakob Molnar[SUP] 2 [/SUP], Sebastian Robert[SUP] 3 [/SUP], Julia Veloso[SUP] 3 [/SUP], Zeljka Trepotec[SUP] 4 [/SUP], Sofie Englisch[SUP] 4 [/SUP], Philip Weinzierl[SUP] 4 [/SUP], Cordula Schick[SUP] 4 [/SUP], Valeria Milani[SUP] 5 [/SUP], Katrin Schweneker[SUP] 6 [/SUP], Bastian Fleischmann[SUP] 7 [/SUP], Josef Scheiber[SUP] 8 [/SUP], Beate Gandorfer[SUP] 4 [/SUP], Axel Kleespies[SUP] 2 [/SUP], Dirk Hempel[SUP] 9 [/SUP], Kristina Riedmann[SUP] 10 [/SUP], Armin Piehler[SUP] 4 [/SUP]
Affiliations
- PMID: 33500147
- DOI: 10.1053/j.seminoncol.2020.12.003
Abstract
SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers' specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.
Keywords: COVID-19; Cancer; Immunity; SARS-CoV2 antibody development.